Correlation Engine 2.0
Clear Search sequence regions

  • adp receptors (1)
  • adult (2)
  • antiplatelet agents (1)
  • help (1)
  • humans (1)
  • P2Y (2)
  • P2Y12 (1)
  • patients (1)
  • platelet (4)
  • receptor (2)
  • ticagrelor (9)
  • Sizes of these terms reflect their relevance to your search.

    Ticagrelor is one of the most recent antiplatelet agents used to inhibit platelet aggregation via blocking the ADP receptors of the subtype P2Y12. It belongs to the non-thienopyridine class. The drug was first discovered by Astra Zeneca and approved for use in 2011 by the FDA. Ticagrelor is usually used for the prevention and treatment of thromboembolism in adult patients with acute coronary syndrome. This chapter include an overview on the physical properties, chemical properties, mode of action, pharmacokinetics and common uses of ticagrelor. In addition, the reported methods of ticagrelor assay will be discussed briefly in order to help analysts to find the most convenient method for its estimation in routine analysis. The methods of synthesis used for the preparation of ticagrelor will also be covered in this chapter. Moreover, the analytical and characterization techniques used to characterize ticagrelor row material are summarized herein. Copyright © 2022 Elsevier Inc. All rights reserved.


    Mohamed Fawzy Kabil, Ahmed S Abo Dena, Ibrahim M El-Sherbiny. Ticagrelor. Profiles of drug substances, excipients, and related methodology. 2022;47:91-111

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35396017

    View Full Text